Amlodipine And Atorvastatin Tablet, Film Coated
Product Images NDC 71335-2924

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Atorvastatin (NDC 71335-2924). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amlodipine Besylate And Atorvastatin Calcium 02)

A line graph showing event rate over time (months) comparing Amlodipine and Placebo groups. The x-axis represents time in months from 0 to 24, and the y-axis shows event rate from 0.00 to 0.25. Two lines indicate event rates for Amlodipine (lower curve) and Placebo (higher curve). The graph includes a statistical summary with P-value=0.003, Hazard Ratio=0.691, and 95% confidence interval (0.54, 0.88). Number of subjects at risk is indicated below the timeline.*

FDA Label Image

Figure 2 (Amlodipine Besylate And Atorvastatin Calcium 03)

A forest plot chart depicting hazard ratios with 95% confidence intervals comparing the effects of Amlodipine versus placebo across different patient subgroups. The subgroups include overall patients, age groups, gender, baseline sitting systolic blood pressure, baseline vessel disease type, vessel stenosis status, and PCI-stent strata. Points indicate hazard ratios with horizontal lines for confidence intervals along a scale from 0.0 to 2.0 favoring either Amlodipine or placebo.*

FDA Label Image

Figure 3 (Amlodipine Besylate And Atorvastatin Calcium 04)

A line graph comparing cumulative incidence (%) over 3.5 years for Atorvastatin versus placebo. The graph shows two lines: a solid line for Atorvastatin with lower cumulative incidence, and a dashed line for placebo with higher cumulative incidence, illustrating a hazard ratio (HR) of 0.64 with confidence interval 0.50-0.83 and p-value of 0.0005.*

FDA Label Image

Figure 4 (Amlodipine Besylate And Atorvastatin Calcium 05)

A line graph comparing the cumulative hazard percentage over time (up to 5 years) for Atorvastatin versus Placebo. The graph shows time to first primary endpoint with Atorvastatin consistently lower than Placebo, including a hazard ratio (HR) of 0.63 with confidence interval 0.48 to 0.83 and p-value of 0.001.*

FDA Label Image

Figure 5 (Amlodipine Besylate And Atorvastatin Calcium 06)

A line graph comparing the percentage of subjects experiencing the first major cardiovascular event over five years for two doses of atorvastatin, 10 mg and 80 mg. The x-axis represents time in years, and the y-axis shows the percentage of subjects. The graph also includes a hazard ratio (HR) of 0.78 with a confidence interval (0.69-0.89) and a p-value of 0.0002, indicating statistical analysis results.*

FDA Label Image

Amlodipine (Amlodipine)

Chemical structure diagrams showing molecular formulas with various chemical groups and bonds. The image depicts the chemical structures of compounds related to the active ingredients, featuring aromatic rings and functional groups such as chlorine, sulfonic acid, and ester moieties.*

FDA Label Image

Atorvastatin-glycol-solvate (Atorvastatin Glycol Solvate)

Chemical structure of Amlodipine and Atorvastatin showing molecular components, including calcium ion (Ca2+) and associated moieties.*

FDA Label Image

Label (Lbl713352924)

Label for Amlodipine and Atorvastatin Tablets USP 10 mg/10 mg, film-coated tablets, 30 count. The label shows the NDC 71335-2924-1 and indicates Rx only. It includes manufacturer Apotex Inc. and relabeler Bryant Ranch Prepack, Inc. Instructions and storage conditions are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.